Lansoprazole in treatment of duodenal ulcer desease

• Published in: Medicinskij sovet no. 3; pp. 125 - 129
• Main Authors: Skvortsov, V. V., Fateeva, O. V., Skvortsova, E. M.
• Format: Journal Article
• Language: English
• Published: Remedium Group LLC 12-05-2019
• Subjects: duodenum ulcer disease; lansoprazole; proton pomp inhibitors
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2019-3-125-129

The duodenum ulcer disease (DUD) has high specific weight among digestive tract pathologies, influencing working capacity and quality of life of patients. Now the tendency of increase in mortality and complications of DUD against the background of decrease in incidence is characteristic of Russia.
For the purpose of identification of the patients infected with H. pylori and also purposes of the most effective H. pylori therapy by him are accepted the recommendations developed by the V Maastricht consensus (Management of Helicobacter pylori infection – the Maastricht V/Florence Consensuns report).
Besides H. pylori therapy to patients the medicines promoting maintenance intragastric рН > 3 not less than 18–20 hours a day are also appointed. Such effect PPI, antacids and H2-receptor antagonists have. PPI are characterized by more expressed antisecretory action and do not cause a tachyphylaxis, than favourably differ from histamine H2-receptor antagonists.
Lancid (lansoprazole) – medicine from the PPI group. It is shown to application for treatment of DUD and for an eradication of H. pylori at the infected patients with erosive and ulcer damages of a stomach and duodenum (as a part of complex therapy). Lansoprazole as a part of Lancid promotes faster healing of ulcer defects and decrease in clinically expressed symptomatology in comparison with omeprazole and pantoprazole.